Interstitial pneumonia possibly due to a novel anticancer drug, TS-1: first case report.
A newly approved oral fluoropyrimidine, TS-1, is a dihydropyrimide dehydrogenase (DPD)-inhibiting fluoropyrimidine (DIF) drug. We describe a case of interstitial pneumonia probably caused by TS-1. A peripheral blood lymphocytes stimulating test (DLST) with TS-1 demonstrated a substantial positive reaction. So far only three cases of TS-1-induced interstitial pneumonia have been reported but the relationship between interstitial pneumonia and TS-1 was demonstrated only in this case. Considering that interstitial pneumonia has also been reported with 5-FU, it is necessary in the future to clarify which component of this drug is directly related to interstitial pneumonia.
Kurakawa
E
E
First Department of Internal Medicine, Tokyo Medical University, Tokyo, Japan.
Kasuga
I
I
Ishizuka
S
S
Yoshida
T
T
Kunisawa
A
A
Minemura
K
K
Utsumi
K
K
Ohyashiki
K
K
D000230:Adenocarcinoma / Q000188:drug therapy; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects*; D004338:Drug Combinations; D006801:Humans; D017563:Lung Diseases, Interstitial / Q000139:chemically induced*; D008297:Male; D010094:Oxonic Acid / Q000009:adverse effects*; D011725:Pyridines / Q000009:adverse effects*; D013274:Stomach Neoplasms / Q000188:drug therapy; D005641:Tegafur / Q000009:adverse effects*
D000964:Antimetabolites, Antineoplastic; D004338:Drug Combinations; D011725:Pyridines; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid